Whereas we used TCZ as a GCs-sparing agent on the basis of published data[17] or EULAR recommendation for the management of large vessel vasculitis.[18] In cases of refractory TA with symptoms of ischemia or progressive vascular inflammation, high doses of GCs or initiation of adjunctive therapy are recommended.[18] Recent randomized clinical trial confirmed the effectiveness of TCZ as GCs-sparing intervention in Japanese patients with TA.[17] These emerging reports suggest a pivotal role of IL-6 in TA pathogenesis, and further investigations are merited. The gene discussed is IL6; the disease is Large vessel vasculitis.